AnaptysBio Inc., a privately-held therapeutic antibody developer, is reporting the development of a new therapeutic antibody to interleukin-33, a pro-inflammatory cytokine associated with tissue damage and increased incidence of atopic dermatitis and severe asthma.
Interleukin-33 (IL-33) has evaded previous antibody technologies, according to AnaptysBio. But the AnaptysBio's SHM-XEL platform has excelled in developing functional leads against biological targets previously thought to be intractable for antibody development.
AnaptysBio's anti-IL-33 lead candidate antibody, ANB020, was developed using the SHM-XEL platform. The company said the drug is the first reported example of a functional anti-IL-33 therapeutic antibody.
"The success of our anti-IL33 program highlights AnaptysBio's competitive advantage in rapidly developing therapeutic antibodies against emerging therapeutic targets," said Hamza Suria, AnaptysBio's president and chief executive officer. "Our business model is focused on leveraging SHM-XEL to develop first-generation antibodies for unmet needs in inflammatory disease, oncology and fibrosis."